SAN FRANCISCO – When cancer patients have hepatitis B virus, prophylaxis to prevent its reactivation during chemotherapy lowers their mortality, but screening for the virus remains uncommon, said researchers from M.D. Anderson Cancer Center in Houston.
Just 17% (1,787) of 10,729 patients who started chemotherapy there during a 3-year study were screened beforehand for hepatitis B virus (HBV), despite recommendations to do so from the Centers for Disease Control and Prevention and other groups.
0 comments:
Post a Comment